QT Interval Prolongation
Cross-source consensus on QT Interval Prolongation from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Interactions
Highlighted claims
- Bedaquiline and delamanid metabolites inhibit the hERG potassium channel, delaying repolarisation and prolonging QT interval. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- QTcB or QTcF above 500 ms or an increase greater than 60 ms from baseline is the established threshold for potentially fatal torsades de pointes risk. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Concurrent use of clofazimine, quinolones, or other QT-prolonging agents compounds the risk of torsades de pointes or sudden cardiac death. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Hypokalaemia increases QT prolongation risk in MDR-TB patients receiving bedaquiline. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Patients older than 45 showed longer QT intervals than younger patients after 1 and 6 months of therapy. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database